Most Recent
‘Nearly every other matter is more important’: Judge in Merck TM battle fed up
"Quite unsatisfactory", is how a judge has described a revived intellectual property dispute between German drug maker Merck KGaA and US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia.
Construction PRO
Lendlease secures Redcliffe Hospital rescue plan contract
Lendlease has been tapped by Queensland as preferred contractor for the Redcliffe Hospital expansion project in Moreton Bay, a key part of the government's hospital rescue plan.
Law firm ‘encouraged’ by J&J’s $7.9B talc settlement in US
Johnson & Johnson has agreed to pay $7.9 billion to resolve multi-district litigation in the US alleging its talcum powder caused cancer, a settlement Shine Lawyers said was a positive development as it readies for a first case management hearing in its class action.
Lender RND presses new claims against BDO, EY on eve of trial
Lender RND Funding wants to revise its case against BDO Advisory and auditor Ernst & Young over advice given to defunct Adelaide company Gen1 Biotechnology, a week out from trial.
Shine gets extension to serve class actions over stomach acid drugs
Shine Lawyers has won a 12-month extension to serve class actions three against drug companies that sell proton pump inhibitors.
National Cancer Foundation wins appeal over ‘Brown Nose Day’ trade mark
The National Cancer Foundation has defeated a challenge to its Brown Nose Day trade mark used for bowel cancer fundraising, with the Full Court finding it is not deceptively similar to SIDS Kids’ Red Nose Day mark. 
Construction PRO
Qld government uses special powers to approve Dreamworld development
The Queensland government has used special powers to approve a major mixed-used development surrounding the Dreamworld theme park, paving the way for new resorts and residential and commercial developments.
ACCC to take deeper look at Zoetis, Neogen merger
The Australian Competition and Consumer Commission has opened a phase 2 review into animal drug company Zoetis' proposed acquisition of Neogen's global animal genomic testing business, saying it would substantially lessen competition in the market for animal gene testing services.
Cosette takes aim at Mayne’s pleading in damages case over failed $672M merger
US drug maker Cosette wants to strike out Mayne Pharma's causation pleading in its suit seeking damages after Cosette allegedly inducing the treasurer to reject their $672 million tie-up.
‘Spectacular waste of money’: J&J class action fights soft class closure
A class action against Johnson & Johnson over alleged ineffective cold medicine has attacked the pharmaceutical company’s application for soft class closure, telling a court the process would produce useless data and only need to be repeated.